No Cover Image

Journal article 132 views 33 downloads

Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy

Tarek Zaidieh, James R. Smith, Karen E. Ball, Qian An

BMC Cancer, Volume: 21, Issue: 1

Swansea University Author: Tarek Zaidieh

  • 60410.VOR.pdf

    PDF | Version of Record

    © The Author(s). 2021, corrected publication 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made

    Download (2.7MB)

Check full text

DOI (Published version): 10.1186/s12885-021-08155-2

Abstract

Associations between mitochondrial genetic abnormalities (variations and copy number, i.e. mtDNAcn, change) and elevated ROS have been reported in cancer compared to normal cells. Since excessive levels of ROS can trigger apoptosis, treating cancer cells with ROS-stimulating agents may enhance their...

Full description

Published in: BMC Cancer
ISSN: 1471-2407
Published: Springer Science and Business Media LLC 2021
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa60410
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2022-07-08T09:12:43Z
last_indexed 2023-01-13T19:20:31Z
id cronfa60410
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-08-03T15:08:56.4107690</datestamp><bib-version>v2</bib-version><id>60410</id><entry>2022-07-08</entry><title>Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy</title><swanseaauthors><author><sid>4349b0c3e21e76e2796efa0a60eff76a</sid><firstname>Tarek</firstname><surname>Zaidieh</surname><name>Tarek Zaidieh</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-07-08</date><deptcode>FGMHL</deptcode><abstract>Associations between mitochondrial genetic abnormalities (variations and copy number, i.e. mtDNAcn, change) and elevated ROS have been reported in cancer compared to normal cells. Since excessive levels of ROS can trigger apoptosis, treating cancer cells with ROS-stimulating agents may enhance their death. This study aimed to investigate the link between baseline ROS levels and mitochondrial genetic abnormalities, and how mtDNA abnormalities might be used to predict cancer cells&#x2019; response to ROS-stimulating therapy.</abstract><type>Journal Article</type><journal>BMC Cancer</journal><volume>21</volume><journalNumber>1</journalNumber><paginationStart/><paginationEnd/><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>1471-2407</issnElectronic><keywords>Mitochondrial DNA, MtDNA variations, MtDNA copy number, Reactive oxygen species, Cisplatin, Dequalinium chloride hydrate, ROS-stimulating therapy, Cancer biomarker</keywords><publishedDay>17</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2021</publishedYear><publishedDate>2021-04-17</publishedDate><doi>10.1186/s12885-021-08155-2</doi><url/><notes/><college>COLLEGE NANME</college><department>Medicine, Health and Life Science - Faculty</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>FGMHL</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>University of Portsmouth;&#xA0;Cara</funders><projectreference/><lastEdited>2022-08-03T15:08:56.4107690</lastEdited><Created>2022-07-08T10:08:25.3382328</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Tarek</firstname><surname>Zaidieh</surname><order>1</order></author><author><firstname>James R.</firstname><surname>Smith</surname><order>2</order></author><author><firstname>Karen E.</firstname><surname>Ball</surname><order>3</order></author><author><firstname>Qian</firstname><surname>An</surname><order>4</order></author></authors><documents><document><filename>60410__24497__77ec97c6b35c4a4a9a838413af217302.pdf</filename><originalFilename>60410.VOR.pdf</originalFilename><uploaded>2022-07-08T10:13:49.2322020</uploaded><type>Output</type><contentLength>2829384</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; The Author(s). 2021, corrected publication 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-08-03T15:08:56.4107690 v2 60410 2022-07-08 Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy 4349b0c3e21e76e2796efa0a60eff76a Tarek Zaidieh Tarek Zaidieh true false 2022-07-08 FGMHL Associations between mitochondrial genetic abnormalities (variations and copy number, i.e. mtDNAcn, change) and elevated ROS have been reported in cancer compared to normal cells. Since excessive levels of ROS can trigger apoptosis, treating cancer cells with ROS-stimulating agents may enhance their death. This study aimed to investigate the link between baseline ROS levels and mitochondrial genetic abnormalities, and how mtDNA abnormalities might be used to predict cancer cells’ response to ROS-stimulating therapy. Journal Article BMC Cancer 21 1 Springer Science and Business Media LLC 1471-2407 Mitochondrial DNA, MtDNA variations, MtDNA copy number, Reactive oxygen species, Cisplatin, Dequalinium chloride hydrate, ROS-stimulating therapy, Cancer biomarker 17 4 2021 2021-04-17 10.1186/s12885-021-08155-2 COLLEGE NANME Medicine, Health and Life Science - Faculty COLLEGE CODE FGMHL Swansea University Another institution paid the OA fee University of Portsmouth; Cara 2022-08-03T15:08:56.4107690 2022-07-08T10:08:25.3382328 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Tarek Zaidieh 1 James R. Smith 2 Karen E. Ball 3 Qian An 4 60410__24497__77ec97c6b35c4a4a9a838413af217302.pdf 60410.VOR.pdf 2022-07-08T10:13:49.2322020 Output 2829384 application/pdf Version of Record true © The Author(s). 2021, corrected publication 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made true eng http://creativecommons.org/licenses/by/4.0/
title Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy
spellingShingle Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy
Tarek Zaidieh
title_short Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy
title_full Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy
title_fullStr Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy
title_full_unstemmed Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy
title_sort Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy
author_id_str_mv 4349b0c3e21e76e2796efa0a60eff76a
author_id_fullname_str_mv 4349b0c3e21e76e2796efa0a60eff76a_***_Tarek Zaidieh
author Tarek Zaidieh
author2 Tarek Zaidieh
James R. Smith
Karen E. Ball
Qian An
format Journal article
container_title BMC Cancer
container_volume 21
container_issue 1
publishDate 2021
institution Swansea University
issn 1471-2407
doi_str_mv 10.1186/s12885-021-08155-2
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description Associations between mitochondrial genetic abnormalities (variations and copy number, i.e. mtDNAcn, change) and elevated ROS have been reported in cancer compared to normal cells. Since excessive levels of ROS can trigger apoptosis, treating cancer cells with ROS-stimulating agents may enhance their death. This study aimed to investigate the link between baseline ROS levels and mitochondrial genetic abnormalities, and how mtDNA abnormalities might be used to predict cancer cells’ response to ROS-stimulating therapy.
published_date 2021-04-17T04:18:30Z
_version_ 1763754230647095296
score 11.014067

Similar Items